Efficacy and Safety of the Aria Pulmonary Endovascular Device in Pulmonary Hypertension
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3187 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Christian Gerges und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hypertension, Pulmonary. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Aria CV, Inc.
Abstract (Originalsprache)
Aims
A common feature of various forms of pulmonary hypertension (PH) is progressive decline of pulmonary arterial compliance (CPA), which correlates with reduced survival. In this acute study, we evaluated feasibility, safety and haemodynamic performance of the Aria pulmonary endovascular device in patients with PH associated with left heart disease (PH-LHD) and chronic lung disease (PH-CLD). Methods and results Eight patients with PH-LHD and 10 patients with PH-CLD were included in this study. The device was placed in the main pulmonary artery via the right femoral vein and was connected by a catheter to a gas-filled reservoir outside the body. During systole, gas shifts from the balloon to the reservoir, leading to deflation of the balloon. In diastole, the gas returns from the reservoir to the balloon, leading to balloon inflation and enhancing diastolic blood flow to the distal pulmonary capillary bed. Haemodynamics were assessed at baseline, and again with device off, device on and device off. The primary safety endpoint was the incidence of serious adverse events through 30 days after the procedure. No complications or investigational device-related serious adverse events occurred. Device activation in PH-LHD and PH-CLD patients decreased pulmonary arterial pulse pressure by 5.6 ± 4.2 mmHg (−12%; p = 0.003) and 4.2 ± 2.2 mmHg (−11%; p < 0.001), increased CPA by 0.4 ± 0.2 ml/mmHg (+23%; p = 0.004) and 0.4 ± 0.3 ml/mmHg (+25%; p = 0.001), and increased right ventricular-to-pulmonary vascular (RV-PV) coupling by 0.24 ± 0.18 (+40%; p = 0.012) and 0.11 ± 0.07 (+21%; p = 0.001), respectively.
Conclusions
Temporary implantation of the Aria endovascular device was feasible and safe. Device activation resulted in acute improvement of CPA and RV-PV coupling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine II, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
- Aria CV, Saint Paul, MN, USA.
- University of Minnesota Medical School, Minneapolis, MN, USA.
ORCID-Profile: Christian Gerges
Förderung
- Aria CV, Inc
Zitieren
APA
Gerges, C., Vollmers, K., Skoro-Sajer, N., Dannenberg, V., Hartig, V., Pritzker, M. R., Scandurra, J., Weir, E. K., & Lang, I. M. (2024). Efficacy and Safety of the Aria Pulmonary Endovascular Device in Pulmonary Hypertension. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3187
Vancouver
Gerges C, Vollmers K, Skoro-Sajer N, Dannenberg V, Hartig V, Pritzker MR, et al. Efficacy and Safety of the Aria Pulmonary Endovascular Device in Pulmonary Hypertension. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3187
BibTeX
@article{Gerges2024,
author = {Gerges, Christian and Vollmers, Karl and Skoro-Sajer, Nika and Dannenberg, Varius and Hartig, Valerie and Pritzker, Marc R and Scandurra, John and Weir, E Kenneth and Lang, Irene M},
title = {Efficacy and Safety of the Aria Pulmonary Endovascular Device in Pulmonary Hypertension},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3187}
}
EUVIMED